Mesoblast's Ryoncil® posts $36M Q4 revenue, $115M full-year, driven by strong pediatric demand.
Mesoblast Limited reported net revenue of $36 million for the fourth quarter and $115 million for the full fiscal year ending June 30, 2026, driven by strong sales of its FDA-approved cellular therapy Ryoncil® for pediatric steroid-refractory acute g...
